173 related articles for article (PubMed ID: 37035750)
61. Cell death-related biomarker SLC2A1 has a significant role in prognosis prediction and immunotherapy efficacy evaluation in pan-cancer.
Wang Y; Wang K; Zhang H; Jia X; Li X; Sun S; Sun D
Front Genet; 2022; 13():1068462. PubMed ID: 36712872
[No Abstract] [Full Text] [Related]
62. Pan-Cancer Analysis of PDIA3: Identifying It as a Potential Biomarker for Tumor Prognosis and Immunotherapy.
Zhang J; Wang K; Hainisayimu T; Li H
Oxid Med Cell Longev; 2022; 2022():9614819. PubMed ID: 36046686
[TBL] [Abstract][Full Text] [Related]
63. Hypoxia Augments Increased HIF-1α and Reduced Survival Protein p-Akt in Gelsolin (GSN)-Dependent Cardiomyoblast Cell Apoptosis.
Yeh YL; Hu WS; Ting WJ; Shen CY; Hsu HH; Chung LC; Tu CC; Chang SH; Day CH; Tsai Y; Huang CY
Cell Biochem Biophys; 2016 Jun; 74(2):221-8. PubMed ID: 27193608
[TBL] [Abstract][Full Text] [Related]
64. Comprehensive Pan-Cancer Analysis of KIF18A as a Marker for Prognosis and Immunity.
Liu T; Yang K; Chen J; Qi L; Zhou X; Wang P
Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830695
[TBL] [Abstract][Full Text] [Related]
65. HIV-1 Vpr Induces Degradation of Gelsolin, a Myeloid Cell-Specific Host Factor That Reduces Viral Infectivity by Inhibiting the Expression and Packaging of the HIV-1 Env Glycoprotein.
Fabryova H; Kao S; Sukegawa S; Miyagi E; Taylor L; Ferhadian D; Saito H; Schaal H; Hillebrand F; Strebel K
mBio; 2023 Feb; 14(1):e0297322. PubMed ID: 36602307
[TBL] [Abstract][Full Text] [Related]
66. Multi-omics analysis of N6-methyladenosine reader IGF2BP3 as a promising biomarker in pan-cancer.
Chen P; Xu J; Cui Z; Wu S; Xie T; Zhang X
Front Immunol; 2023; 14():1071675. PubMed ID: 36761737
[TBL] [Abstract][Full Text] [Related]
67. Immunological Role and Prognostic Value of APBB1IP in Pan-Cancer Analysis.
Ge Q; Li G; Chen J; Song J; Cai G; He Y; Zhang X; Liang H; Ding Z; Zhang B
J Cancer; 2021; 12(2):595-610. PubMed ID: 33391455
[No Abstract] [Full Text] [Related]
68. A systematic pan-cancer analysis identifies RIOK3 as an immunological and prognostic biomarker.
Li J; Sun R; He L; Sui G; Di W; Yu J; Su W; Pan Z; Zhang Y; Zhang J; Ren F
Am J Transl Res; 2022; 14(6):3750-3768. PubMed ID: 35836879
[TBL] [Abstract][Full Text] [Related]
69. ORC6, a novel prognostic biomarker, correlates with T regulatory cell infiltration in prostate adenocarcinoma: a pan-cancer analysis.
Lin Y; Zhang Y; Tuo Z; Gao L; Ding D; Bi L; Yu D; Lv Z; Wang J; Chen X
BMC Cancer; 2023 Mar; 23(1):285. PubMed ID: 36978046
[TBL] [Abstract][Full Text] [Related]
70. A comprehensive pan-cancer analysis on the immunological role and prognostic value of
Yang Y; Jiang L; Wang S; Chen H; Yi M; Wu Y; Li Z; Fang X
Transl Cancer Res; 2022 Sep; 11(9):3187-3208. PubMed ID: 36237259
[TBL] [Abstract][Full Text] [Related]
71. Identification of CDK2-Related Immune Forecast Model and ceRNA in Lung Adenocarcinoma, a Pan-Cancer Analysis.
Liu TT; Li R; Huo C; Li JP; Yao J; Ji XL; Qu YQ
Front Cell Dev Biol; 2021; 9():682002. PubMed ID: 34409029
[TBL] [Abstract][Full Text] [Related]
72. Impact of actin filament stabilization on adult hippocampal and olfactory bulb neurogenesis.
Kronenberg G; Gertz K; Baldinger T; Kirste I; Eckart S; Yildirim F; Ji S; Heuser I; Schröck H; Hörtnagl H; Sohr R; Djoufack PC; Jüttner R; Glass R; Przesdzing I; Kumar J; Freyer D; Hellweg R; Kettenmann H; Fink KB; Endres M
J Neurosci; 2010 Mar; 30(9):3419-31. PubMed ID: 20203201
[TBL] [Abstract][Full Text] [Related]
73. A pan-cancer analysis of the oncogenic role of ribonucleotide reductase subunit M2 in human tumors.
Li Y; Fu W; Geng Z; Song Y; Yang X; He T; Wu J; Wang B
PeerJ; 2022; 10():e14432. PubMed ID: 36518297
[TBL] [Abstract][Full Text] [Related]
74. Pan-Cancer Analysis of the N6-Methyladenosine Eraser FTO as a Potential Prognostic and Immunological Biomarker.
Zhao C; Liu Y; Ju S; Wang X
Int J Gen Med; 2021; 14():7411-7422. PubMed ID: 34744452
[TBL] [Abstract][Full Text] [Related]
75. Comprehensive pan-cancer analysis of role of GPRASP1, associated with clinical outcomes, immune microenvironment, and immunotherapeutic efficiency in pancreatic cancer.
Du J; Chen Y; Liu G; Zeng Q; Zhou N; Du D
Pathol Res Pract; 2023 Mar; 243():154374. PubMed ID: 36801507
[TBL] [Abstract][Full Text] [Related]
76. Pan-Cancer Integrated Analysis Identification of SASH3, a Potential Biomarker That Inhibits Lung Adenocarcinoma Progression.
Chen X; Yuan Y; Ren W; Zhou F; Huang X; Pu J; Niu X; Jiang X
Front Oncol; 2022; 12():927988. PubMed ID: 35756681
[TBL] [Abstract][Full Text] [Related]
77. Comprehensive Pan-Cancer Analysis of GINS2 for Human Tumour Prognosis and as an Immunological Biomarker.
Meng W; Jiang Z; Zhang X; Cai B; Ma L; Guan Y
Comput Math Methods Med; 2022; 2022():3119721. PubMed ID: 36466552
[TBL] [Abstract][Full Text] [Related]
78. Four differentially expressed genes can predict prognosis and microenvironment immune infiltration in lung cancer: a study based on data from the GEO.
Wen S; Peng W; Chen Y; Du X; Xia J; Shen B; Zhou G
BMC Cancer; 2022 Feb; 22(1):193. PubMed ID: 35184748
[TBL] [Abstract][Full Text] [Related]
79. Integrative Pan-Cancer Analysis of KIF15 Reveals Its Diagnosis and Prognosis Value in Nasopharyngeal Carcinoma.
Mi J; Ma S; Chen W; Kang M; Xu M; Liu C; Li B; Wu F; Liu F; Zhang Y; Wang R; Jiang L
Front Oncol; 2022; 12():772816. PubMed ID: 35359374
[TBL] [Abstract][Full Text] [Related]
80. RecQ mediated genome instability 2 (
Wei W; Ying X; Chen L; Sun Q; Lu X; Xia Y; Xu R; Zhu Z; Zhang D; Tang Q; Li L; Xie J; Yu H
Aging (Albany NY); 2022 May; 14(9):4107-4136. PubMed ID: 35552266
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
